Lucida Medical

Investor: IW Capital

IW Capital has led an £8.7 million investment into Lucida Medical, a UK-based healthtech firm developing AI-powered prostate cancer diagnostics from MRI scans.Summary of transaction details:Value: £8.7 millionSector: Healthcare & BiotechAdvisor: Not disclosedKey Entities: Target – Lucida Medical; Lead Investor – IW Capital; Other investors – XTX Ventures, Macmillan Cancer SupportLocation: London, United KingdomNote: The funding will support expansion of Lucida’s AI diagnostic service within the NHS, aiming to improve early prostate cancer detection amid rising incidence rates.

Investor: IW Capital

UK healthtech startup Lucida Medical has successfully closed an £8.7 million funding round led by IW Capital, with additional participation from XTX Ventures and Macmillan Cancer Support, to expand its AI-driven cancer diagnostics platform.Summary of transaction details:Value: £8.7 MillionSector: Healthcare & BiotechAdvisor: Not disclosedKey Entities: Lucida Medical, IW Capital, XTX Ventures, Macmillan Cancer SupportLocation: United KingdomNote: The capital injection will primarily fund the pursuit of US FDA regulatory clearance and the expansion of the company's Pi™ diagnostic platform beyond prostate cancer, addressing critical radiologist shortages and diagnostic delays within the NHS and broader healthcare markets.

Investor: IW Capital

Lucida Medical, an AI-powered diagnostic startup based in Cambridge, has successfully secured £8.7 million in a recent funding round. This investment is set to bolster its efforts in developing and deploying AI solutions for prostate cancer diagnosis from MRI scans, aiming to support clinicians and meet rising demands within the NHS.Summary of transaction details:Value: £8.7 millionSector: Healthcare & Biotech, DeepTech & AIAdvisor: None mentionedKey Entities: Lucida Medical (Target), IW Capital (Lead Investor), Macmillan Cancer Support, XTX Ventures (Investors)Location: Cambridge, UKNote: This funding round underscores the growing investor confidence in AI-driven healthcare solutions, particularly those addressing critical bottlenecks in diagnostics and improving patient outcomes. The participation of Macmillan Cancer Support highlights the societal impact and potential of Lucida Medical's technology in revolutionising cancer care.